Patient-provider communication about the use of medical cannabis for cancer symptoms: a cross-sectional study.

Kea Turner, Oliver T Nguyen, Jessica Y Islam, Sahana Rajasekhara, Yessica C Martinez, Amir Alishahi Tabriz, Brian D Gonzalez, Heather S L Jim, Kathleen M Egan
{"title":"Patient-provider communication about the use of medical cannabis for cancer symptoms: a cross-sectional study.","authors":"Kea Turner, Oliver T Nguyen, Jessica Y Islam, Sahana Rajasekhara, Yessica C Martinez, Amir Alishahi Tabriz, Brian D Gonzalez, Heather S L Jim, Kathleen M Egan","doi":"10.1093/jncimonographs/lgad026","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There has been limited study regarding patient-provider communication about medical cannabis for cancer symptom management. To address this gap, this study assesses the determinants and prevalence of patient-provider communication about the use of medical cannabis for cancer symptoms at a National Cancer Institute-designated Comprehensive Cancer Center.</p><p><strong>Methods: </strong>Individuals who completed cancer treatment from July 2017 to December 2019 were invited to participate in a survey regarding medical cannabis. An electronic survey was administered in English and Spanish from August to November 2021 and completed by 1592 individuals (response rate = 17.6%).</p><p><strong>Results: </strong>About one-third (33.5%) of participants reported discussing medical cannabis for cancer symptom management with a health-care provider. Controlling for other factors, individuals with malnutrition and/or cachexia had higher odds (odds ratio [OR] = 2.30, 95% confidence interval [CI] = 1.50 to 3.53) of reporting patient-provider discussions compared with individuals without malnutrition and/or cachexia. Similarly, individuals with nausea had higher odds (OR = 1.94, 95% CI = 1.44 to 2.61) of reporting patient-provider discussions compared with individuals without nausea. A smaller percentage (15.6%) of participants reported receiving a recommendation for medical cannabis for cancer symptom management. Among individuals who reported using cannabis, a little over one-third (36.1%) reported not receiving instructions from anyone on how to use cannabis or determine how much to take.</p><p><strong>Conclusions: </strong>Overall, our study suggests that patient-provider communication about medical cannabis for cancer symptom management is limited. As interest and use of medical cannabis continues to grow among cancer patients, there is a need to ensure patients have access to high quality patient-provider communication.</p>","PeriodicalId":73988,"journal":{"name":"Journal of the National Cancer Institute. Monographs","volume":"2024 66","pages":"298-304"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303860/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Cancer Institute. Monographs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jncimonographs/lgad026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: There has been limited study regarding patient-provider communication about medical cannabis for cancer symptom management. To address this gap, this study assesses the determinants and prevalence of patient-provider communication about the use of medical cannabis for cancer symptoms at a National Cancer Institute-designated Comprehensive Cancer Center.

Methods: Individuals who completed cancer treatment from July 2017 to December 2019 were invited to participate in a survey regarding medical cannabis. An electronic survey was administered in English and Spanish from August to November 2021 and completed by 1592 individuals (response rate = 17.6%).

Results: About one-third (33.5%) of participants reported discussing medical cannabis for cancer symptom management with a health-care provider. Controlling for other factors, individuals with malnutrition and/or cachexia had higher odds (odds ratio [OR] = 2.30, 95% confidence interval [CI] = 1.50 to 3.53) of reporting patient-provider discussions compared with individuals without malnutrition and/or cachexia. Similarly, individuals with nausea had higher odds (OR = 1.94, 95% CI = 1.44 to 2.61) of reporting patient-provider discussions compared with individuals without nausea. A smaller percentage (15.6%) of participants reported receiving a recommendation for medical cannabis for cancer symptom management. Among individuals who reported using cannabis, a little over one-third (36.1%) reported not receiving instructions from anyone on how to use cannabis or determine how much to take.

Conclusions: Overall, our study suggests that patient-provider communication about medical cannabis for cancer symptom management is limited. As interest and use of medical cannabis continues to grow among cancer patients, there is a need to ensure patients have access to high quality patient-provider communication.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
关于使用医用大麻治疗癌症症状的患者与医护人员沟通情况:一项横断面研究。
背景:有关医用大麻治疗癌症症状的患者与医护人员沟通的研究十分有限。为了填补这一空白,本研究评估了在国家癌症研究所指定的综合癌症中心,患者与医护人员就使用医用大麻治疗癌症症状进行沟通的决定因素和普遍程度:邀请在 2017 年 7 月至 2019 年 12 月期间完成癌症治疗的个人参与有关医用大麻的调查。2021 年 8 月至 11 月期间,以英语和西班牙语进行了电子调查,共有 1592 人完成了调查(回复率 = 17.6%):结果:约三分之一(33.5%)的参与者表示曾与医疗服务提供者讨论过医用大麻治疗癌症症状的问题。在控制其他因素的情况下,与没有营养不良和/或恶病质的人相比,有营养不良和/或恶病质的人报告与患者和医护人员进行讨论的几率更高(几率比 [OR] = 2.30,95% 置信区间 [CI] = 1.50 至 3.53)。同样,与没有恶心症状的患者相比,有恶心症状的患者报告患者与医护人员讨论的几率更高(OR = 1.94,95% 置信区间 [CI] = 1.44 至 2.61)。有较小比例(15.6%)的参与者报告收到了医用大麻治疗癌症症状的建议。在报告使用大麻的人中,有略高于三分之一(36.1%)的人报告未从任何人那里获得关于如何使用大麻或确定服用量的指导:总体而言,我们的研究表明,患者与医护人员就医用大麻治疗癌症症状进行的沟通是有限的。随着癌症患者对医用大麻的兴趣和使用不断增加,有必要确保患者能够获得高质量的患者-提供者沟通。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
0
期刊最新文献
Challenges to and considerations of designing cancer prevention trials. Design and analysis considerations for investigating patient subgroups of interest within cancer clinical trials. Design considerations and challenges in the CHinA National CancEr Screening (CHANCES) trial and Tomosynthesis Mammographic Imaging Screening Trial (TMIST). Global perspectives on patient-centered outcomes: advancing patient-centered cancer clinical trials globally. Intracluster correlation coefficients from cluster randomized trials conducted within the NCI Community Oncology Research Program (NCORP).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1